1. Summit Therapeutics (NASDAQ:SMMT)
Upside Potential: 296.3%
Summit Therapeutics (NASDAQ:SMMT) ranks first in our list of the 10 biotechnology stocks with more than 50% upside potential, offering one of the most striking growth projections among biotech companies currently covered by Wall Street analysts. The company is focused on developing innovative oncology treatments, particularly its promising therapy ivonescimab, which is being studied as a treatment for non-small cell lung cancer.
Ivonescimab represents a new type of bispecific antibody therapy designed to simultaneously block PD-1 signaling while targeting angiogenesis pathways involved in tumor growth. This dual-mechanism approach aims to improve treatment outcomes compared with existing immunotherapy drugs.
Investor interest increased significantly after the company confirmed that the U.S. FDA had accepted its application for ivonescimab, supported by results from the global Phase 3 HARMONi clinical trial. The agency has set a regulatory decision date of November 14, 2026.
If approved, the therapy could address a significant treatment gap among lung cancer patients who have progressed after targeted therapies. Analysts estimate that roughly 14,000 patients in the United States each year may be eligible for treatment under the proposed indication.
In addition, the company already has commercial exposure to the drug in China through a partnership with Akeso, which could provide early revenue opportunities. With a projected median price target suggesting nearly 300% upside potential, Summit Therapeutics currently stands as the most aggressive growth candidate on the list for investors seeking high-upside biotechnology stocks and innovative oncology therapies.
READ ALSO: Top 10 Small-Cap FDA Catalyst Biotech Stocks and Top 5 Best Biotech Stocks of February 2026.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
